Sanofi and Regeneron achieved a modest victory for their cholesterol lowering drug Praluent, but it is unlikely the trial will dramatically improve a challenging landscape.
from Forbes Real Time https://www.forbes.com/sites/larryhusten/2018/03/10/the-odyssey-trial-ends-well-but-will-it-be-enough/
via IFTTT
No comments:
Post a Comment